Phosphodiesterase 2 and Its Isoform a as Therapeutic Targets in the Central Nervous System Disorders

CNS Neurol Disord Drug Targets. 2023 Sep 25. doi: 10.2174/1871527323666230811093126. Online ahead of print.ABSTRACTCyclic adenosine monophosphates (cAMP) and cyclic guanosine monophosphate (cGMP) are two essential second messengers, which are hydrolyzed by phosphodiesterase's (PDEs), such as PDE-2. Pharmacological inhibition of PDE-2 (PDE2A) in the central nervous system improves cAMP and cGMP signaling, which controls downstream proteins related to neuropsychiatric, neurodegenerative, and neurodevelopmental disorders. Considering that there are no specific treatments for these disorders, PDE-2 inhibitors' development has gained more attention in the recent decade. There is high demand for developing new-generation drugs targeting PDE2 for treating diseases in the central nervous and peripheral systems. This review summarizes the relationship between PDE-2 with neuropsychiatric, neurodegenerative, and neurodevelopmental disorders as well as its possible treatment, mainly involving inhibitors of PDE2.PMID:37855295 | DOI:10.2174/1871527323666230811093126
Source: CNS and Neurological Disorders Drug Targets - Category: Drugs & Pharmacology Authors: Source Type: research